Neonatal outcome after exposure to indomethacin in utero: a retrospective case cohort study - 28/08/11
Reprint requests: Jack Ludmir, MD, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Pennsylvania Hospital, 800 Spruce St, Philadelphia, PA 19107.Abstract |
Objective |
This study was undertaken to determine the clinical outcome for neonates who were exposed to indomethacin during gestation.
Study design |
We identified 124 infants with in utero exposure to indomethacin and matched them to 124 infants whose mothers did not receive indomethacin. The two groups were matched for gestational age at birth, sex, and exposure to antenatal betamethasone. Sixty-two of the indomethacin-exposed infants were born within 48 hours of last exposure. These infants were also compared with their matched controls.
Results |
There were no significant differences between the indomethacin-exposed infants and control infants in birth weight, Apgar scores, frequency of cesarean section deliveries, and multiple gestation. The incidence of respiratory distress syndrome, need for surfactant treatment, patent ductus arteriosus, necrotizing enterocolitis, and intraventricular hemorrhage was similar between the indomethacin-exposed group and the control group. Indomethacin-exposed infants who were born within 48 hours of last exposure had similar incidence of respiratory distress syndrome but greater need for surfactant treatment (P=.02) compared with controls. All other complication rates were similar.
Conclusion |
Indomethacin exposure in our study was not associated with increased neonatal complications for infants delivered within or beyond 48 hours of last exposure.
Le texte complet de cet article est disponible en PDF.Keywords : Indomethacin, tocolytics, neonatal complications
Plan
 | Presented at the Twenty-Third Annual Meeting of the Society for Maternal-Fetal Medicine, San Francisco, Calif, February 3-8, 2003. |
Vol 189 - N° 3
P. 782-785 - septembre 2003 Retour au numéro
Article précédent
- Unexplained elevated maternal serum ⍺-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes
- Sujata Chandra, Heather Scott, Linda Dodds, Carolyn Watts, Claire Blight, Michiel Van den Hof
- Differential expression of c-fos in a mouse model of fetal alcohol syndrome
- Sarah H Poggi, Katie M Goodwin, Joanna M Hill, Douglas E Brenneman, Elisabetta Tendi, Sergio Schninelli, Catherine Y Spong
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?